Facts and fiction: Cellular models for high throughput screening for HIV-1 reactivating drugs

Current HIV Research

Volumn 9, Issue 8, 2011, Pages 568-578

  Planelles, Vicente ^a   Wolschendorf, Frank ^b   Kutsch, Olaf ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Drug screening; HIV 1 latency

Indexed keywords

4 3',4' DICHLOROANILINO 6 METHOXYQUINOLINE; HISTONE DEACETYLASE INHIBITOR; QUINOLINE DERIVATIVE; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; DRUG SCREENING; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; SIGNAL TRANSDUCTION; STIMULUS; T LYMPHOCYTE; VIRUS LATENCY; VIRUS REACTIVATION;

ANTI-HIV AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HIV-1; HUMANS; MODELS, BIOLOGICAL; T-LYMPHOCYTES; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84856487534     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211798998826     Document Type: Article

References (86)

1. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326(6114): 711-3.
2. Alcami J, Lain de Lera T, Folgueira L, et al. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. Embo J 1995; 14(7): 1552-60.
3. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5(6): 651-5.
4. van Praag RM, Prins JM, Roos MT, et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001; 21(3): 218-26.
5. Kulkosky J, Nunnari G, Otero M, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002; 186(10): 1403-11.
6. Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992; 327(10): 736.
7. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119(11): 3473-86.
8. Xing S, Bullen CK, Shroff NS, et al. Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation. J Virol 85(12): 6060-4.
9. Wolschendorf F, Duverger A, Jones J, et al. Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 2010; 84(17): 8712-20.
10. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1996; 15(5): 1112-20.
11. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996; 5(4-5): 245-53.
12. Sheridan PL, Mayall TP, Verdin E, Jones KA. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 1997; 11(24): 3327-40.
13. He G, Ylisastigui L, Margolis DM. The regulation of HIV-1 gene expression: the emerging role of chromatin. DNA Cell Biol 2002; 21(10): 697-705.
14. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. Aids 2004; 18(8): 1101-8.
15. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009; 113(1): 58-65.
16. Duverger A, Jones J, May J, et al. Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol 2009; 83(7): 3078-93.
17. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366(9485): 549-55.
18. Archin NM, Cheema M, Parker D, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 5(2): e9390.
19. Siliciano JM, Siliciano RF. Targeting HIV reservoirs with valproic acid. Hopkins HIV Rep 2005; 17(5): 8-9.
20. Smith SM. Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology 2005; 2: 56.
21. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195(6): 833-6.
22. Archin NM, Eron JJ, Palmer S, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. Aids 2008; 22(10): 1131-5.
23. Han Y, Lassen K, Monie D, et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004; 78(12): 6122-33.
24. Shan L, Yang HC, Rabi SA, et al. Influence of Host Gene Transcription Level and Orientation on HIV-1 Latency in a Primary-Cell Model. J Virol 85(11): 5384-93.
25. Han Y, Lin YB, An W, et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 2008; 4(2): 134-46.
26. Lenasi T, Contreras X, Peterlin BM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 2008; 4(2): 123-33.
27. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. Embo J 2007; 26(24): 4985-95.
28. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007; 81(20): 10914-23.
29. Pearson R, Kim YK, Hokello J, et al. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol 2008; 82(24): 12291-303.
30. Williams SA, Chen LF, Kwon H, et al. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25(1): 139-49.
31. Keedy KS, Archin NM, Gates AT, et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol 2009; 83(10): 4749-56.
32. du Chene I, Basyuk E, Lin YL, et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. Embo J 2007; 26(2): 424-35.
33. Marban C, Suzanne S, Dequiedt F, et al. Recruitment of chromatinmodifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. Embo J 2007; 26(2): 412-23.
34. Kim YK, Bourgeois CF, Pearson R, et al. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. Embo J 2006; 25(15): 3596-604.
35. Klatt A, Zhang Z, Kalantari P, et al. The receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity. J Immunol 2008; 180(3): 1670-7.
36. Zhang Z, Klatt A, Gilmour DS, Henderson AJ. Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex. J Biol Chem 2007; 282(23): 16981-8.
37. Ping YH, Rana TM. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates PTEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J Biol Chem 2001; 276(16): 12951-8.
38. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A 2006; 103(31): 11473-8.
39. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010; 84(13): 6425-37.
40. Folks TM, Clouse KA, Justement J, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989; 86(7): 2365-8.
41. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci ASA. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238(4828): 800-2.
42. Folks TM, Powell D, Lightfoote M, et al. Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med 1986; 164(1): 280-90.
43. Perez VL, Rowe T, Justement JS, et al. An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. J Immunol 1991; 147(9): 3145-8.
44. Butera ST, Perez VL, Wu BY, Nabel GJ, Folks TM. Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. J Virol 1991; 65(9): 4645-53.
45. Emiliani S, Van Lint C, Fischle W, et al. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A 1996; 93(13): 6377-81.
46. Emiliani S, Fischle W, Ott M, et al. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol 1998; 72(2): 1666-70.
47. Yukl S, Pillai S, Li P, et al. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology 2009; 387(1): 98-108.
48. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1(12): 1284-90.
49. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387(6629): 183-8.
50. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188(1): 83-91.
51. Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002; 76(17): 8776-86.
52. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. Embo J 2003; 22(8): 1868-77.
53. Winslow BJ, Pomerantz RJ, Bagasra O, Trono D. HIV-1 latency due to the site of proviral integration. Virology 1993; 196(2): 849-54.
54. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM. Dynamics of HIV-1 recombination in its natural target cells. Proc Nat Acad Sci 2004; 101(12): 4204-9.
55. Micheva-Viteva S, Pacchia AL, Ron Y, Peltz SW, Dougherty JP. Human immunodeficiency virus type 1 latency model for highthroughput screening. Antimicrob Agents Chemother 2005; 49(12): 5185-8.
56. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 1999; 4(2): 67-73.
57. Micheva-Viteva S, Kobayashi Y, Edelstein LC, et al. Highthroughput Screening Uncovers a Compound That Activates Latent HIV-1 and Acts Cooperatively with a Histone Deacetylase (HDAC) Inhibitor. J Biol Chem 2011; 286(24): 21083-91.
58. Jones J, Rodgers J, Heil M, et al. High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds. Assay Drug Dev Technol 2007; 5(2): 181-89.
59. Ochsenbauer-Jambor C, Jones J, Heil M, Zammit KP, Kutsch O. Tcell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques 2006; 40(1): 91-100.
60. Saleh S, Solomon A, Wightman F, et al. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007; 110(13): 4161-4.
61. Brady T, Agosto LM, Malani N, et al. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. Aids 2009; 23(12): 1461-71.
62. Agosto LM, Yu JJ, Dai J, et al. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 2007; 368(1): 60-72.
63. Marini A, Harper JM, Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 2008; 181(11): 7713-20.
64. Sahu GK, Lee K, Ji J, et al. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ Tlymphocytes. Virology 2006; 355(2): 127-37.
65. Marsden MD, Burke BP, Zack JA. HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes. Virology.
66. Bosque A, Planelles V. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 2011; 53(1): 54-61.
67. Edwards BS, Young SM, Ivnitsky-Steele I, et al. High-content screening: flow cytometry analysis. Methods Mol Biol 2009; 486: 151-65.
68. Kuckuck FW, Edwards BS, Sklar LA. High throughput flow cytometry. Cytometry 2001; 44(1): 83-90.
69. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006; 3(5): 361-8.
70. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. Embo J 2001; 20(7): 1726-38.
71. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 2005; 122(2): 169-82.
72. Choudhary SK, Margolis DM. Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol 51: 397-418.
73. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15(8): 893-900.
74. Pace MJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirs and latency models. Virology 411(2): 344-54.
75. Homann D, Teyton L, Oldstone MB. Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med 2001; 7(8): 913-9.
76. Tokoyoda K, Zehentmeier S, Hegazy AN, et al. Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 2009; 30(5): 721-30.
77. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003; 4(9): 835-42.
78. Hellerstein MK, Hoh RA, Hanley MB, et al. Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest 2003; 112(6): 956-66.
79. Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 1992; 360(6401): 264-5.
80. McLean AR, Michie CA. In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci U S A 1995; 92(9): 3707-11.
81. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008; 122(1): 22-8.
82. Dahl V, Palmer S. Establishment of drug-resistant HIV-1 in latent reservoirs. J Infect Dis 2009; 199(9): 1258-60.
83. Bosque A, Famiglietti M, Weyrich A, Goulston C, Planelles V. Homeostatic Proliferation Fails to Efficiently Reactivate HIV-1 Latently Infected Central Memory CD4+ T Cells. PLoS Pathog 2011; In Press.
84. Archin NM, Espeseth A, Parker D, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25(2): 207-12.
85. Jones J, Kosloff BR, Benveniste EN, Shaw GM, Kutsch O. Amphotericin-B-mediated reactivation of latent HIV-1 infection. Virology 2005; 331(1): 106-16.
86. Kutsch O, Levy DN, Kosloff BR, Shaw GM, Benveniste EN. CD154-CD40-induced reactivation of latent HIV-1 infection. Virology 2003; 314(1): 261-70.